Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4<sup>+</sup>CD8<sup>+</sup> T cells.

Cell reports. Medicine·2026

Same author

ERK builds a population of short-lived nascent adhesions that produce persistent edge protrusion and cell migration.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026

Same author

Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors.

JCO precision oncology·2026

Same author

Complications of PI to PIII hemipelvic resections for intermediate and malignant tumours : a systematic review and meta-analysis.

Bone & joint open·2026

Same author

Team Approach: Diagnosis and Management of Pediatric Pelvic Ewing Sarcoma.

JBJS reviews·2026

Search research articles

Related Experiment Video

Updated: May 12, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

BCOR-Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study.

Diego M Montoya-Cerrillo¹, Mark G Evans², Andrew Elliott²

¹Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.

Genes, Chromosomes & Cancer

|September 13, 2025

Summary

This summary is machine-generated.

BCOR mutations in conventional and dedifferentiated chondrosarcoma are linked to more aggressive disease. These genetic aberrations correlate with larger tumors, metastasis, and higher T category, indicating poorer prognosis.

Keywords:

BCOR chondrosarcoma conventional dedifferentiated

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Related Experiment Videos

Last Updated: May 12, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Area of Science:

Oncology
Genetics
Pathology

Background:

Conventional and dedifferentiated chondrosarcoma are malignant bone tumors producing cartilaginous matrix.
Dedifferentiated chondrosarcoma is an aggressive subtype with a poor prognosis.
IDH1/2, COL2A1, and TP53 are commonly mutated genes in chondrosarcoma; IDH1/2 mutations are also found in precursor lesions and other cancers.

Purpose of the Study:

To investigate the clinicopathological features of BCOR-mutated chondrosarcomas.
To determine if BCOR mutations are associated with distinct patterns of biological progression compared to BCOR-wildtype tumors.

Main Methods:

Clinicopathological analysis of 12 cases of BCOR-mutated conventional and dedifferentiated chondrosarcomas.
Comparison against a control group of 15 BCOR-wildtype (WT) cases.
Analysis of BCOR alterations, including missense and nonsense mutations leading to loss-of-function.

Main Results:

BCOR mutations were found in 5% of conventional and dedifferentiated chondrosarcomas.
BCOR mutations were significantly associated with larger tumor size (p=0.024).
BCOR mutations correlated with metastasis at diagnosis (p≤0.001) and higher T category (p=0.009).

Conclusions:

BCOR genetic aberrations in chondrosarcoma are associated with adverse clinical features.
BCOR mutations indicate a more aggressive clinical presentation.
Further research is needed to fully elucidate the impact of BCOR mutations on patient outcomes.